What to know about compounded versions of Wegovy; Genentech weighs slow-walking ovarian cancer therapy

Taking stock of the drug industry, from the lab to the medicine chest

August 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Toby Talbot/AP STAT+ | Supreme Court blocks Purdue bankruptcy plan that would shield Sacklers from lawsuits "This is a good sign" for those who filed lawsuits over OxyContin marketing" said Carl Tobias, a law professor at the University of Richmond. By Ed Silverman STAT+ | What to know about concerns raised about compounded versions of Novo Nordisk's Wegovy STAT explains what to know about concerns raised about compounded versions of Novo Nordisk's Wegovy and Ozempic. By Ed Silverman STAT+ | EPA fines Roche's Genentech unit for hazardous waste violations EPA inspectors found Genentech stored waste without a permit and failed to properly monitor hazardous waste air emissions. By Ed Silverman Genentech STAT+ | Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform Genentech is considering slow-walking an ovarian cancer therapy to make more money under drug pricing reform. By Rachel Cohrs STAT+ | Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. By Allison DeAngelis and Elaine Chen Listen: Your guide to Wegovy's blockbuster heart study In the wake of a big trial of Novo Nordisk's obesity drug Wegovy, STAT's Elaine Chen joins us to explain what we know and don't know. By Damian Garde and Allison DeAngelis and Adam Feuerstein Molly Ferguson/STAT STAT+ | Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials If Anavex's drug fails to achieve the pre-determined goals, the thinking apparently goes, just make a post-hoc change to the study goals. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser